Tags

Type your tag names separated by a space and hit enter

Effects of pentoxifylline on severe intermittent claudication.
Angiology. 1987 Sep; 38(9):651-6.A

Abstract

Pentoxifylline has been shown to improve treadmill walking distances under blinded, controlled conditions in patients with intermittent claudication. From the pooled data of a blinded, controlled, randomized, multicenter trial, the data from all enrolled patients with severe claudication (less than 70 m on treadmill at baseline) were evaluated. The treadmill data from these more severely ill patients were analyzed separately as a "severe subset" (placebo n = 17; pentoxifylline n = 21). No differences between the two treatment groups were observed in demography, history, or baseline treadmill walking distances. The initial claudication distance (ICD) improved 68% over baseline with pentoxifylline and 12% with placebo (p = .012) after twenty-four weeks of treatment. A new, derived efficacy variable was developed, "minimum distance walked," which tended to minimize psychological effects on treadmill performance. Over sixteen to twenty-four weeks of treatment, the pentoxifylline group improved 49% over baseline and the placebo group 3% (p = .019), when the "minimum distance walked" measurement was used. In this controlled trial the subset of patients with severe intermittent claudication benefited from pentoxifylline therapy.

Authors+Show Affiliations

Department of Surgery, New York University Medical Center, New York.No affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

3310744

Citation

Reich, T, and D Gillings. "Effects of Pentoxifylline On Severe Intermittent Claudication." Angiology, vol. 38, no. 9, 1987, pp. 651-6.
Reich T, Gillings D. Effects of pentoxifylline on severe intermittent claudication. Angiology. 1987;38(9):651-6.
Reich, T., & Gillings, D. (1987). Effects of pentoxifylline on severe intermittent claudication. Angiology, 38(9), 651-6.
Reich T, Gillings D. Effects of Pentoxifylline On Severe Intermittent Claudication. Angiology. 1987;38(9):651-6. PubMed PMID: 3310744.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of pentoxifylline on severe intermittent claudication. AU - Reich,T, AU - Gillings,D, PY - 1987/9/1/pubmed PY - 1987/9/1/medline PY - 1987/9/1/entrez SP - 651 EP - 6 JF - Angiology JO - Angiology VL - 38 IS - 9 N2 - Pentoxifylline has been shown to improve treadmill walking distances under blinded, controlled conditions in patients with intermittent claudication. From the pooled data of a blinded, controlled, randomized, multicenter trial, the data from all enrolled patients with severe claudication (less than 70 m on treadmill at baseline) were evaluated. The treadmill data from these more severely ill patients were analyzed separately as a "severe subset" (placebo n = 17; pentoxifylline n = 21). No differences between the two treatment groups were observed in demography, history, or baseline treadmill walking distances. The initial claudication distance (ICD) improved 68% over baseline with pentoxifylline and 12% with placebo (p = .012) after twenty-four weeks of treatment. A new, derived efficacy variable was developed, "minimum distance walked," which tended to minimize psychological effects on treadmill performance. Over sixteen to twenty-four weeks of treatment, the pentoxifylline group improved 49% over baseline and the placebo group 3% (p = .019), when the "minimum distance walked" measurement was used. In this controlled trial the subset of patients with severe intermittent claudication benefited from pentoxifylline therapy. SN - 0003-3197 UR - https://www.unboundmedicine.com/medline/citation/3310744/Effects_of_pentoxifylline_on_severe_intermittent_claudication_ L2 - http://journals.sagepub.com/doi/full/10.1177/000331978703800901?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -